Text Size

Evaluation of Wound Biofilm in Acute and Chronic Wounds

This study has been withdrawn prior to enrollment.
(withdrawn as MSU approval obained)
Sponsor:
Information provided by (Responsible Party):
Randall Wolcott, Southwest Regional Wound Care Center
ClinicalTrials.gov Identifier:
NCT00764348
First received: September 30, 2008
Last updated: September 6, 2011
Last verified: September 2011
History of Changes
  Purpose

Patients who present to a wound care center for management of their wounds will be evaluated clinically to establish if their wounds are chronic or acute. These patients will undergo standard of care management of their wounds. If debridement is indicated for the patient, the patient will be asked to participate in a study. Once the standard of care debridement is complete, the material debrided from the wound, instead of being discarded into a biohazard bag, will be prepared for shipment. The samples will then be shipped to the Center for Biofilm Engineering where microscopic evaluation will be conducted on the material. Conclusion will be made from that analysis.


Condition Intervention
Wounds
 Other: no treatment

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Evaluation of Wound Biofilm in Acute and Chronic Wounds

Further study details as provided by Southwest Regional Wound Care Center:

Primary Outcome Measures:
  • It is important for all wound care providers to firmly grasp the wound biofilm concept, its importance in delayed wound healing, and how it differs from a planktonic bacterial concept. [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

traumatic, diabetic foot ulcer, decubitus ulcer, venous leg ulcer


Enrollment: 0
Groups/Cohorts Assigned Interventions
no treatment Other: no treatment

Detailed Description:

A planktonic concept of the bacteria present on the surface of a chronic wound is no longer viable. Microscopic studies show that biofilm is present on chronic wounds yet does not seem to be prominent on the surface of acute wounds. Biofilm is able to neutralize our host defenses and commandeer host systems, and possesses an impressive array of defenses and virulence factors. Clinically we see a significant difference in the healing behavior between chronic and acute wounds. Also, suppression of biofilm using multiple simultaneous strategies including debridement, anti-biofilm agents, specific biocides, antibiotics and advanced technologies improves wound healing. This suggests biofilm plays an important role in delayed wound healing.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Acute and Chronic Wounds

  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Randall Wolcott, Prinicipal Investigator, Southwest Regional Wound Care Center
ClinicalTrials.gov Identifier: NCT00764348     History of Changes
Other Study ID Numbers: 56-RW-002
Study First Received: September 30, 2008
Last Updated: September 6, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Southwest Regional Wound Care Center:
Acute and Chronic Wounds

ClinicalTrials.gov processed this record on June 13, 2013